<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129398</url>
  </required_header>
  <id_info>
    <org_study_id>8228-042</org_study_id>
    <secondary_id>MK-8228-042</secondary_id>
    <secondary_id>195020</secondary_id>
    <nct_id>NCT04129398</nct_id>
  </id_info>
  <brief_title>MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)</brief_title>
  <official_title>A Phase 3, Open-Label, Single-Arm Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MK-8228 (Letermovir) for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) of Letermovir
      (LET) administered as prevention of cytomegalovirus (CMV) infection and disease in adult
      Japanese kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to week 52 post-transplant</time_frame>
    <description>Percentage of participants with one or more adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued from study drug</measure>
    <time_frame>Up to week 28 post-transplant</time_frame>
    <description>Percentage of participants who discontinued from study drug due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adjudicated CMV disease or undergone anti-CMV treatment</measure>
    <time_frame>Up to Week 52 post-transplant</time_frame>
    <description>Percentage of participants with adjudicated CMV disease or undergone anti-CMV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adjudicated CMV disease</measure>
    <time_frame>Up to Week 52 post-transplant</time_frame>
    <description>Percentage of participants with adjudicated CMV disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with quantifiable CMV DNAemia</measure>
    <time_frame>Up to Week 52 post-transplant</time_frame>
    <description>Percentage of participants with quantifiable CMV DNAemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of plasma Letermovir - oral treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Area under the concentration-time curve to the end of the dosing period (AUCtau) of plasma LET - oral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) of plasma Letermovir - oral treatment</measure>
    <time_frame>Pre-dose on Weeks 1, 2,4, 6, 8, 10, 12, 16, 20, 24 and 28</time_frame>
    <description>Trough concentration (Ctrough) of plasma LET - oral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of plasma Letermovir - oral treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Maximum concentration (Cmax) of plasma LET - oral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of plasma Letermovir - oral treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Time to Cmax (Tmax) of plasma LET - oral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance at steady state (CLss/F) of plasma Letermovir - oral treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Apparent clearance at steady state (CLss/F) of plasma LET - oral treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of plasma Letermovir - IV treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Area under the concentration-time curve to the end of the dosing period (AUCtau) of plasma LET - IV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough) of plasma Letermovir - IV treatment</measure>
    <time_frame>Pre-dose on Weeks 2,4, 6, 8, 10, 12, 16, 20, 24 and 28</time_frame>
    <description>Trough concentration (Ctrough) of plasma LET - IV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of infusion (Ceoi) of plasma Letermovir - IV treatment</measure>
    <time_frame>Any day between Days 6-10: at end of infusion (up to 1 hour)</time_frame>
    <description>Concentration at the end of infusion (Ceoi) of plasma LET - IV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance at steady state (CLss) of plasma Letermovir - IV treatment</measure>
    <time_frame>Any day between Days 6-10: pre-dose, 1, 2.5, 5, 8 and 24 hrs post-dose</time_frame>
    <description>Clearance at steady state (CLss) of plasma LET - IV treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <condition>Cytomegalovirus Disease</condition>
  <arm_group>
    <arm_group_label>Letermovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letermovir oral or intravenous (IV) formulation will be administered once daily for up to 28 weeks, beginning up to 7 days post-transplant. The dose will be 240 mg once daily for participants receiving concomitant cyclosporin A (CsA) and 480 mg once daily for participants not receiving CsA. IV infusion will be administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir tablet</intervention_name>
    <description>A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
    <other_name>PREVYMIS™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir IV</intervention_name>
    <description>IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
    <other_name>PREVYMIS™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets recipient and/or donor CMV Immunoglobulin G (IgG) serostatus.

          -  Anticipates receiving a primary or secondary allograft kidney at the time of screening
             and have received a primary or secondary allograft kidney at the time of allocation.

          -  Is within 0 (i.e., day of transplantation) to 7 days (inclusive) post-kidney
             transplant at the time of allocation.

          -  Is a Japanese male or female from 18 years to any years of age inclusive, at the time
             of signing the informed consent.

          -  Female is not pregnant or breastfeeding, and is not a woman of childbearing potential
             (WOCBP); but if a WOCBP, she is using an acceptable contraceptive method, or is
             abstinent from heterosexual intercourse, and must have a negative highly sensitive
             pregnancy test within 72 hours before the first dose of study intervention.

        Exclusion Criteria:

          -  Has received a previous solid organ transplant or hematopoietic stem cell transplant
             (HSCT).

          -  Is a multi-organ transplant recipient (e.g., kidney-pancreas).

          -  Has a history of CMV disease or suspected CMV disease within 6 months prior to
             allocation.

          -  Has positive results on CMV assay and/or CMV antigen test at any time between the
             completion of the transplant surgery and time of allocation.

          -  Has suspected or known hypersensitivity to active or inactive ingredients of LET
             formulations.

          -  Is on dialysis (for the purposes of this protocol dialysis includes hemofiltration) or
             plasmapheresis at the time of allocation.

          -  Has Child-Pugh Class C severe hepatic insufficiency at screening.

          -  Has post-transplant renal function of creatinine clearance (CrCl) ≤10 mL/min at
             allocation (measured locally).

          -  Has both moderate hepatic insufficiency AND moderate-to-severe renal insufficiency at
             screening.

          -  Has any uncontrolled infection on the day of allocation.

          -  Has documented positive results for human immunodeficiency virus antibody (HIV-Ab)
             test at any time prior to allocation, or for hepatitis C virus antibody (HCV-Ab) and
             with detectable HCV RNA within 90 days prior to allocation or hepatitis B surface
             antigen (HBsAg) within 90 days prior to allocation.

          -  Requires mechanical ventilation, or is hemodynamically unstable, at the time of
             allocation.

          -  Has a history of malignancy ≤5 years prior to signing informed consent.

          -  Has received within 30 days prior to allocation or plans to receive during the study
             any of the following: CMV immune globulin; any investigational CMV antiviral
             agent/biologic therapy.

          -  Has received any dose of LET prior to allocation.

          -  Has received within 7 days prior to allocation or plans to receive during the study
             any anti-CMV drug therapy.

          -  Is a user of recreational or illicit drugs or has had a recent history (within the
             last year) of drug or alcohol abuse or dependence.

          -  Is taking or plans to take any of the prohibited medications listed in the protocol.

          -  Is currently participating or has participated in a study with an unapproved
             investigational compound or device within 28 days, or 5× half-life of the
             investigational compound.

          -  Has previously participated in this study or any other study involving LET.

          -  Has previously participated or is currently participating in any study involving
             administration of a CMV vaccine or another CMV investigational agent, or is planning
             to participate in a study of a CMV vaccine or another CMV investigational agent during
             the course of this study.

          -  Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from
             the time of consent through at least 28 days following cessation of study therapy.

          -  Is expecting to donate eggs starting from the time of consent through at least 28 days
             following cessation of study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daini Hospital ( Site 0002)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81528321121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital ( Site 0004)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81117262211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital ( Site 0003)</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81668795111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital ( Site 0001)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81333538111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

